Cytek Biosciences, Inc.
NASDAQ:CTKB
4.2 (USD) • At close March 14, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|
| Assets: | ||||||
| Current Assets: | ||||||
| Cash & Cash Equivalents
| 98.716 | 167.299 | 296.601 | 364.618 | 165.231 | 30.122 |
| Short Term Investments
| 179.145 | 95.111 | 44.548 | 0 | 0 | 0 |
| Cash and Short Term Investments
| 277.861 | 262.41 | 341.149 | 364.618 | 165.231 | 30.122 |
| Net Receivables
| 60.588 | 56.12 | 48.864 | 29.76 | 18.104 | 17.746 |
| Inventory
| 43.893 | 60.877 | 48.154 | 32.171 | 23.018 | 18.434 |
| Other Current Assets
| 14.104 | 12.653 | 17.933 | 4.914 | 2.269 | 1.463 |
| Total Current Assets
| 396.446 | 392.06 | 454.02 | 432.052 | 208.622 | 67.765 |
| Non-Current Assets: | ||||||
| Property, Plant & Equipment, Net
| 28.13 | 29.258 | 27.565 | 5.851 | 2.14 | 1.041 |
| Goodwill
| 16.663 | 16.183 | 10.144 | 10.144 | 0.476 | 0.476 |
| Intangible Assets
| 20.128 | 23.084 | 4.331 | 4.739 | 0.274 | 0.263 |
| Goodwill and Intangible Assets
| 36.791 | 39.267 | 14.475 | 14.883 | 0.75 | 0.739 |
| Long Term Investments
| 0 | 1.6 | 1.6 | 0 | 0 | 0.25 |
| Tax Assets
| 33.374 | 30.487 | 20.459 | 9.249 | 7.378 | 0.629 |
| Other Non-Current Assets
| 4.759 | 1.785 | 1.357 | 1.665 | 1.089 | -0.063 |
| Total Non-Current Assets
| 103.054 | 102.397 | 65.456 | 31.648 | 11.357 | 2.596 |
| Total Assets
| 499.5 | 494.457 | 519.476 | 463.7 | 219.979 | 70.361 |
| Liabilities & Equity: | ||||||
| Current Liabilities: | ||||||
| Account Payables
| 5.529 | 3.032 | 4.805 | 3.034 | 2.944 | 2.342 |
| Short Term Debt
| 0 | 3.009 | 12.616 | 0 | 2.772 | 0 |
| Tax Payables
| 3.559 | 1.297 | 1.667 | 3.879 | 1.034 | 0.571 |
| Deferred Revenue
| 25.492 | 22.695 | 12.986 | 7.081 | 4.289 | 3.471 |
| Other Current Liabilities
| 33.083 | 26.193 | 26.651 | 19.187 | 15.497 | 14.655 |
| Total Current Liabilities
| 67.663 | 56.226 | 49.04 | 32.16 | 26.536 | 21.039 |
| Non-Current Liabilities: | ||||||
| Long Term Debt
| 7.552 | 11.127 | 14.583 | 0 | 0 | 0 |
| Deferred Revenue Non-Current
| 0 | 15.132 | 13.124 | 9.79 | 3.456 | 1.782 |
| Deferred Tax Liabilities Non-Current
| 0 | 0 | 4.048 | 0.777 | 0.404 | 0.629 |
| Other Non-Current Liabilities
| 28.548 | 18.908 | 17.183 | 14.949 | 206.015 | 89.241 |
| Total Non-Current Liabilities
| 36.1 | 45.167 | 44.89 | 24.739 | 209.471 | 91.023 |
| Total Liabilities
| 103.763 | 101.393 | 93.93 | 56.899 | 236.007 | 112.062 |
| Equity: | ||||||
| Preferred Stock
| 0 | 0 | 519.476 | 463.305 | 194.319 | 74.653 |
| Common Stock
| 0.129 | 0.131 | 0.135 | 0.126 | 0.023 | 0.021 |
| Retained Earnings
| -35.199 | -29.178 | -17.03 | -18.19 | -22.607 | -42.018 |
| Accumulated Other Comprehensive Income/Loss
| 0.016 | -1.275 | -0.697 | 0.897 | 0.065 | -0.147 |
| Other Total Stockholders Equity
| 430.791 | 423.386 | 442.887 | 423.625 | -194.319 | -74.653 |
| Total Shareholders Equity
| 395.737 | 393.064 | 425.295 | 406.458 | -16.028 | -41.701 |
| Total Equity
| 395.737 | 393.064 | 425.546 | 406.801 | -16.028 | -41.701 |
| Total Liabilities & Shareholders Equity
| 499.5 | 494.457 | 519.476 | 463.7 | 219.979 | 70.361 |